Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06915363 · ClinicalTrials.gov registry record · NA

BioPoly® Partial Resurfacing Knee Implant IDE

A NA study of Knee Osteoarthritis and Knee Pain Chronic, sponsored by BioPoly.

Recruiting
Registry status
NA
Development phase
152
Enrollment target
1
Study location

NCT06915363: Recruiting NA study of Knee Osteoarthritis and Knee Pain Chronic, sponsored by BioPoly.

NCT06915363 is a NA study of Knee Osteoarthritis and Knee Pain Chronic that is actively recruiting participants, run by BioPoly. The registered enrollment target is 152 participants, below the 303-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06915363, a NA study of Knee Osteoarthritis and Knee Pain Chronic, is actively recruiting participants, sponsored by BioPoly.

RECRUITING
Registry status
NA
Development phase
152 participants
Enrollment target
1
Study location

Study Summary

The goal of this randomized controlled clinical trial is to demonstrate the safety and effectiveness of the BioPoly® Partial Resurfacing Knee Implant for the treatment of cartilage defects of the distal femur in adult patients with knee pain and symptoms who are candidates for surgical intervention of the knee compared to outcomes for the control group. The primary effectiveness endpoint is Month 24 composite clinical success (CCS) defined by: * no secondary surgical intervention (SSI) and * an improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points. Researchers will compare the CCS for the investigational device group to a control group receiving the standard of care, either microfracture or debridement). Subjects randomized to the investigational group will receive the BioPoly Knee device and those randomized to the control group will receive the current standard of care, either microfracture or debridement.

Primary Outcome

An improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points. If this criteria is met, the subject will be considered as a success relative to the measure of the Clinical Composite Success for effectiveness.

Interventions

  • DEVICE BioPoly
  • PROCEDURE surgical standard of care (SSOC)

Study Locations (1)

Indiana

  • Dupont Hospital - Fort Wayne

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2025-03-17
Est. Completion 2028-12
Phase NA
BioPoly

1 total trials

What NCT06915363 shows while recruiting

NCT06915363 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 303-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (50% lower).

The record links to 6 conditions, with Knee Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which BioPoly is the first listed.

NCT06915363 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT06915363 about?

NCT06915363 is a clinical study titled "BioPoly® Partial Resurfacing Knee Implant IDE". The goal of this randomized controlled clinical trial is to demonstrate the safety and effectiveness of the BioPoly® Partial Resurfacing Knee Implant for the treatment of cartilage defects of the distal femur in adult patients with knee pain and symptoms who are candidates for surgical intervention ...

What is the current status of trial NCT06915363?

This trial is currently recruiting. It is a NA study. The enrollment target is 152 participants. The study started on 2025-03-17. Estimated completion is 2028-12.

What conditions does trial NCT06915363 study?

This clinical trial studies the following conditions: Knee Osteoarthritis, Knee Pain Chronic, Cartilage Damage, Cartilage Defects of the Knee, Cartilage or Osteochondral Defects in the Knee.

What interventions are being tested in trial NCT06915363?

The interventions under investigation include: BioPoly (DEVICE), surgical standard of care (SSOC) (PROCEDURE).

Who is sponsoring clinical trial NCT06915363?

This trial is sponsored by BioPoly, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06915363 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Knee Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06915363's enrollment target sits among peer trials

152 33rd of 101 higher than 69 of 101 other Knee Osteoarthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Knee Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03328078 · 152 participants · Phase 1

    CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • NCT04458532 · 152 participants · NA

    Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer

  • NCT04858334 · 152 participants · Phase 2

    APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  • NCT04993859 · 152 participants

    Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06915363, the US trial registry maintained by the National Library of Medicine. NCT06915363 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.